Skip to main content

Angeles Alvarez Secord, MD

Angeles Secord, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765

My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.

Education and Training

  • Resident, Obstetrics & Gynecology, Duke University, 1994 - 1998
  • M.D., University of Washington, 1994


  • Duke University Medical Center, Masters of Health Sciences in Clinical Research, 2005-2011


Dr. Secord's research interests include elucidating the underlying genetic biology of angiogenesis in ovarian cancer, innovative clinical trial design, development of novel targeted therapies for personalized medicine, identification of biomarkers to direct anti-neoplastic therapy, and the incorporation of patient-reported outcomes in clinical trials. She has studied the regulation of angiogenesis in ovarian cancer for approximately 20 years and has recently extended our research to include the immunophenotype of the tumor microenvironment. 



Lopez-Acevedo, M, Havrilesky, LJ, Broadwater, G, Kamal, AH, Abernethy, AP, Berchuck, A, Secord, AA, Tulsky, JA, Valea, F, and Lee, PS. "Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer." Gynecologic Oncology 130, no. 1 (2013): 156-161.

Full Text

Alvarez Secord, A, Bernardini, MQ, Broadwater, G, Grace, LA, Huang, Z, Baba, T, Kondoh, E, Sfakianos, G, Havrilesky, LJ, and Murphy, SK. "TP53 Status is Associated with Thrombospondin1 Expression In vitro. (Published online)" Front Oncol 3 (2013): 269-.

Full Text

Lopez-Acevedo, M, Zhang, C, Secord, AA, Lee, PS, Havrilesky, LJ, and Berchuck, A. "Predictors of failure to perform pelvic peritoneal cytology in endometrial cancer staging surgery." JOURNAL OF CLINICAL ONCOLOGY 30, no. 34 (December 1, 2012).

Full Text

Zhang, C, Secord, AA, Lee, PS, Havrilesky, LJ, and Berchuck, A. "Predictors of failure to perform pelvic peritoneal cytology in endometrial cancer staging surgery." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30, no. 34_suppl (December 2012): 201-.


Cantrell, LA, Havrilesky, L, Moore, DT, O'Malley, D, Liotta, M, Secord, AA, Nagel, CI, Cohn, DE, Fader, AN, Wallace, AH, Rose, P, and Gehrig, PA. "A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma." Gynecologic Oncology 127, no. 1 (October 2012): 22-26.

Full Text

Secord, AA, Teoh, DK, Barry, WT, Yu, M, Broadwater, G, Havrilesky, LJ, Lee, PS, Berchuck, A, Lancaster, J, and Wenham, RM. "A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 18, no. 19 (October 2012): 5489-5498.

Full Text

Aghajanian, C, Sill, MW, Secord, AA, Powell, MA, and Steinhoff, M. "Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study." Gynecologic Oncology 126, no. 3 (September 2012): 424-427.

Full Text

Franasiak, J, Ko, EM, Kidd, J, Secord, AA, Bell, M, Boggess, JF, and Gehrig, PA. "Physical strain and urgent need for ergonomic training among gynecologic oncologists who perform minimally invasive surgery." Gynecol Oncol 126, no. 3 (September 2012): 437-442.

Full Text

Fader, AN, Seamon, LG, Escobar, PF, Frasure, HE, Havrilesky, LA, Zanotti, KM, Secord, AA, Boggess, JF, Cohn, DE, Fowler, JM, Skafianos, G, Rossi, E, and Gehrig, PA. "Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centers." Gynecol Oncol 126, no. 2 (August 2012): 180-185.

Full Text

Secord, AA, and Gehrig, PA. "Obesity: Too big a problem to ignore." Gynecol Oncol 126, no. 2 (August 2012): 274-276.

Full Text